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ABSTRACT 
 
Background. Methylisothiazolinone (MI) has caused an epidemic of contact allergy in Europe 
documented with data from many countries, but no studies from Croatia exist. Also data is 
lacking on severity of MI disease, impact on quality of life and prognosis. 
Objectives. To determine the frequency of MI contact allergy among Croatian dermatitis 
patients, identify causative exposures, qualify impact of disease and study prognosis.  
Methods. Data was collected for consecutive dermatitis patients with MI contact allergy 
during one year patch tested in a University Hospital Center in Zagreb, Croatia.  
Results. MI contact allergy was diagnosed in 13.2% of 798 tested patients. Most frequent 
dermatitis locations were the hands (76%) and face (61%). In 89.3% of patients the MI 
contact allergy was found to be of current relevance. Dishwashing liquids, laundry 
detergents and shampoos were most frequently responsible for the dermatitis. A 
considerable severity and impact on daily living of disease was found at first consultation 
with a statistically significant decrease in both at follow-up 3 months following patch testing. 
Conclusions. An exceptionally high rate of contact allergy to MI was found. The severity of 
MI allergic contact dermatitis and impact on daily living documents the need for prevention. 
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INTRODUCTION 
Methylisothiazolinone (MI) has recently been added to the European baseline series (1). An 
unprecedented rise in MI contact allergy has been seen primarily due to stay-on cosmetic 
products, but also other exposures such as paints and soaps (2-5). Data has been collected 
from many countries, but not from Croatia, where patch testing with MI has been performed 
since March 2015. Many studies on MI contact allergy have been published in recent years, 
but none of these has included severity assessments, impact on quality of life or prognosis. 
The aim of the study was to identify current and causative exposures to MI in Croatian 
patients with MI allergy, qualify reaction patterns and course of disease.  
 
PATIENTS AND METHODS 
Consecutive dermatitis patients who were patch tested in the Department of Dermatology 
and Venereology, University Hospital Center Zagreb between 2 November 2015 and 3 
November 2016, were eligible for inclusion in the study, provided they were diagnosed with 
contact allergy to MI (see below). At inclusion, basic characteristics of the patients such as 
sex, age, occupation, site of dermatitis, history of atopic dermatitis, previous patch test 
results, and onset of dermatitis were documented. Furthermore, the dermatologist graded 
the severity of the dermatitis on a visual analogue scale (VAS) from 0 (no dermatitis) to 100 
(very severe dermatitis), in terms of a physician’s global assessment. Patients were asked to 
indicate how much their skin disease had influenced their daily life negatively by thinking of 
the past week on a VAS scale from 0 (no influence) to 100 (could not be worse), that is, to 
provide the patient’s own global assessment.   
 
  
All patients were patch tested with the baseline series (Imunološki zavod, Zagreb, Croatia; 
and Chemotechnique, Vellinge, Sweden) using 8 mm Finn Chambers® (Epitest, Tuusula, 
Finland) on Scanpor tape® (Norgesplaster, Vennesla, Norway) applied to the upper back and 
left in place for 2 days. A micropipette was used to apply 15 µl of each MI 0.2% aq. and 
MI/MCI 0.01% aq. to the filter paper in a Finn Chamber. Patches were read at day (D)2, D3 
and D7 according to the ESCD guideline on patch testing (6). A positive response was defined 
as a +, ++ or +++ reaction. 
On D7 patients with a positive reaction to MI 0.2% were asked to bring all their cosmetics, 
cleaning products and other types of relevant products, also from work place. It was 
recorded if MI or MCI/MI were present in any of these products. In case one or more of 
these products were the cause of the current dermatitis, more details about these products 
were retrieved. Further it was recorded whether the patients had experienced symptoms in 
newly painted rooms. A follow-up visit about 3 months after patch testing was made, where 
patients and physicians were asked again to give their global assessment concerning severity 
of dermatitis and negative influence of dermatitis on daily living, respectively, in a fashion 
identical to the initial visit.  
Data were recorded anonymously in an online documentation system (SoSci survey; 
https://www.soscisurvey.de) and processed and analyzed using the statistical software 
package R (version 3.4.2, https://r-project.org). Besides descriptive statistics, the Wilcoxon 
signed-rank test was used for pre/post comparison of VAS score for severity and impact of 
disease. A p-value of < 0.05 was considered significant. 
 
 
 
  
RESULTS 
In total 798 patients (198 males and 600 females) were tested to the baseline series. Of 
these, 51 (6.4%) were positive to MCI/MI (1.4% males, and 5% females) and 105 (13.2%) to 
MI (2.1% males and 11.0% females). Forty (5%) patients were positive both to MI and 
MCI/MI, and 116 (14.5%) patients were positive either to MCI/MI or MI respectively.  
Out of the 105 patients who were positive to MI 75 patients [11 (14.7%) males and 64 
(85.3%) females] were included in the study. Median age was 42 years. Main occupations 
were office workers (n=20), student/pensioners (n=12) and housewives (n=4). Five were 
unemployed, three were hairdressers/beauticians and only one was painter. In total 22 
patients did not want to participate in the study, and 8 patients did not show up after 3 
months and did not reply to phone calls and/or letters. 
Eleven patients had atopic dermatitis, current (9) and/or past (5). The onset of disease was 
in 48 (69%) cases between 2013 and 2016, most (n=23) in 2015. Only 3 (4%) had a known 
contact allergy to MI and/or MI/MCI previously proven by patch testing. In total 69 (92%) 
patients had ongoing dermatitis at the first consultation; location was in 76% (n=57) the 
hands, in 61% (n=46) the face, including 51% (n=38) with periorbital involvement. In 42 
(56%) patients, three or more anatomical sites (with the categorization chosen) were 
affected. In the remaining 33 patients, the most common combinations were hands and 
arms (n=11), hands and feet, and neck and periorbital (n=2 each). In total 18 (24%) of 
patients had experienced airborne symptoms mainly dermatitis (n=15), but also rhinitis 
(n=3); asthma-like symptoms (n=1) and/or conjunctivitis (n=2) was reported. 
 
 
 
  
Exposures 
According to the documentation of products to which the patients had been exposed, 71 
were exposed to products containing MI (between 1 product, in 16 patients, to 11 products, 
in 2 patients; the mean number of products was 3.8). Exposure to products containing 
MCI/MI was noted in 57 patients (between 1 in 19 patients to 11 products in one patient, 
mean number of products 2.4). Exposure to privately used products was by far dominating, 
with a share of 89 % (n=67) and a mean number of products of 3.4, while occupationally 
used products were documented in just 27% of patients (n=20). The main product groups in 
the context of private exposure were wet wipes, liquid soaps, shampoos, bath and shower 
gels and hand creams (Table 1). Additionally, liquid laundry detergents (n=21) and fabric 
softeners (n=14) were frequently identified to contain MI or MCI/MI.   
Product type Number of products with: 
    MI                  MCI/MI 
Used in 
Private life 
Used  
occupationally 
Creams/Lotions     
-body 3 3 2 0 
-face 7 4 6 0 
-eyes 3 1 2 0 
-hands 16 10 14 1 
-feet 1 0 1 0 
Sunscreens 3 1 3 0 
Self-tanning 0 0 0 0 
Deodorant     
-spray 3 2 2 0 
-roll-on/stick 5 5 6 1 
Make-up     
-face masks 3 2 2 1 
-eye make-up 2 0 1 0 
-tinted bases 0 0 0 0 
-make-up remover 9 4 9 1 
Wet wipes 34 24 31 6 
Hairstyling     
-gels/mousse 3 2 3 0 
 -sprays 2 1 2 0 
Nail care 0 0 0 0 
Mouths washes 0 0 0 0 
Rinse-of cosmetics     
-liquid soap 27 20 24 6 
-bath/shower gel 20 13 18 0 
-shampoo 27 20 22 0 
-conditioner 3 3 3 0 
  
Shaving products 1 0 1 0 
Cleaning agents 23 17 21 7 
Household cleaning spray 17 11 17 4 
Dishwashing liquid 23 14 21 2 
Paints 4 3 3 0 
Glues 1 0 1 1 
Cutting oils 1 0 0 1 
Table 1: Number of products containing MI or MCI/MI and used by the patients (determined from ingredient 
labelling, materials safety data sheets, contact to manufacturer or chemical analysis) 
 
Current relevance  
In 67 of 75 (89.3%) patients the MI contact allergy was found to be of current relevance. 
Products were identified, which had caused or contributed to the current dermatitis. On 
average 2.87 products were given per patient as responsible for the dermatitis. The most 
frequent types of product found relevant were dishwashing liquids (36%), laundry 
detergents and shampoo (34.7% each) (Table 2).  
 Number In % of all 
relevant products 
Dishwashing liquid 27 36 
Laundry detergent 26 34.7 
Shampoo 26 34.7 
Wet wipes 23 30.7 
Fabric softener 19 25.3 
Cleaning agent 15 20 
Shower gel 10 13.3 
Liquid soap 8 10.7 
Hand cream 7 9.3 
Wall paint 4 5.3 
Face cream 4 5.3 
  
Conditioner 3 4 
Roll-on deodorant 3 4 
Make up remover 2 2.7 
Table 2: The most frequent types of product found relevant for the current dermatitis. 
 
Severity, QoL and course of disease 
Severity was assessed by the physician at the first consultation, when patch testing was 
planned using a VAS from 0 (no dermatitis) to 100 (very severe dermatitis) and again at a 
follow-up visit at least 3 months following patch testing. At the first consultation the severity 
was median 40 with 30 and 80 as quartiles; range 5 to 100. At the follow-up visit the severity 
VAS was median 5 with 0 and 17.5 as quartiles; range 0 to 70. This is illustrated in figure 1. 
The improvement in severity was statistically significant (p<0.001 by Wilcoxon signed-rank 
test). 
At the same points in time the patients were asked to indicate how much their skin disease 
had influenced their daily life negatively by thinking of the past week on a VAS scale from 0 
(no influence) to 100 (could not be worse). At their first consultation the negative impact 
was scored to 100 as a median with 70 and 100 as quartiles; range 15 to 100. At the follow-
up visit the negative impact was scored to 5 points as median, with 0 and 20 as quartiles; 
range 0-100. This is illustrated in figure 2 and the improvement was statistically significant 
(p<0.001 by Wilcoxon signed-rank test). 
Twelve patients (16%) had to take sick-leave due to their MI contact allergy, 2 (2.7%) was 
admitted to hospital for treatment and for 4 patients (5.3%) the MI allergy had occupational 
consequences resulting in job loss or job change.  
 
  
DISCUSSION 
This is the first study which has examined the prevalence of MI contact allergy in Croatia. 
The results were exceptional. In total 13.2% of consecutively patch tested patients had 
contact allergy to MI, defined by a positive patch test. In comparison 6.0% of consecutively 
patch tested patients from 8 European countries had a positive patch test to MI in 2015, 
with a top range of 13.0% in Finland in a special center for occupational skin disease (7). In 
previous investigations from 2013 in individual countries high rates were found in Portugal 
with 10.9% positive patch test reactions to MI (8) 11.1% on The British Isles (9) and 13.2% in 
Finland (10). If the number of patients having positive patch test reactions to the mixture 
MI/MCI are added to those with MI reactions, one in five patients in Croatia are allergic to 
isothiazolinones, which are permitted in cosmetic products. In the current investigation most 
reactions were caused by consumer products. This is also reflected in that many more 
females than males were allergic to MI (2.1% males; 11.0% females), which is also seen in 
other populations (11).  
The cases identified in Croatia were in the majority (69%) incident cases with on-set within 
the past 3 years reflecting an on-going epidemic. In a study from Leeds (12) trends of MI 
contact allergy were followed from 2008 to 2015. Even though a decreasing prevalence to 
both MI and MCI/MI were seen after 2013, where the first recommendation to ban MI in 
cosmetic products from the Scientific Committee on Consumer Safety was given (13), 11 out 
of 16 cases (69%) had their first symptoms after 2013 (12). In the European multicenter 
study mentioned above 68% (86/126) of patients also developed symptoms after 2013 (7). In 
this study from Croatia the most frequent types of product found relevant to the dermatitis 
(causative) were dishwashing liquids (36%), laundry detergents and shampoo (34.7% each). 
Wet wipes as stay-on cosmetics (30.7%) were among the top ranking causative products, 
  
which is interesting as wet wipes were implicated in the first cases reported on MI contact 
allergy from cosmetics (14). Hand and facial creams accounted for 9.3% and 5.3% of 
causative products, which may show a beginning effect of the announced ban in stay-on 
cosmetic products (15); fully implemented by 17. February 2017, from which date stay-on 
cosmetics containing MI must not be sold any more in Europe. There is a changing pattern in 
product types causing MI contact allergy from stay-on cosmetics to wash-off and house hold 
products. In a recent Swiss market survey of 1948 consumer products it was shown that only 
7.6% of all cosmetic products were found to contain isothiazolinone. Shampoo was the 
product category with the highest percentage of isothiazolinones (33.8%), followed by 
shower gel (13.3%) and wet wipes (11.6%) (16). A higher percentage of detergents (42.7%) 
than of cosmetics were found to contain isothiazolinones, most often benzisothiazolinone 
(BIT) in 31.2% and MI in 31.1%, followed by MCI (9.9%). High concentrations were 
particularly found in detergents (16). These results connect well with the patterns of 
causative products in the current investigation. 
In total 18 (24%) of patients had experienced airborne symptoms mainly dermatitis (n=15), 
but also rhinitis; asthma-like symptoms and/or conjunctivitis was reported.    
Isothiazolinones are used in many water-based paints (17,18). MI was found 55/60 (91.7%) 
of paints bought in five different European countries in concentrations up to 142 ppm (18). 
MI is volatile and can be found for weeks in indoor air after indoor decorating has been done 
(19). Airborne contact dermatitis and airway symptoms in MI allergic individuals have been 
reported in children and adults from many countries (2,4,7). There seems to be no effective 
solution in place for this severe problem.  
       
  
This is one of the few studies investigating the course of disease, impact on daily living and 
the potential positive effects of being patch tested and informed about relevant allergy 
(20,21,23-25), in this case to MI. A major impact of contact allergy to MI was documented. 
The patients scored the negative impact of their skin disease at the first consultation as 
‘could not be worse’, corresponding to median 100 on a VAS from 0-100. At the same time 
the dermatologist assessed the severity of the skin disease on a VAS as median 40 with 30 
and 80 as quartiles, on a 0-100 scale. The many sources of MI exposures contribute to the 
severe state of disease in these patients as well as hidden exposure from products, where 
there is no ingredient labelling requirement (22). The study also showed a clear benefit of 
diagnosing MI allergy by patch testing, informing patients on how to avoid exposures and 
treatment. 
At the follow-up visit after 3 months the negative impact of disease was scored to 5 points as 
median by the patients and so was severity of disease assessed by the dermatologists.  
In an English study follow-up was made 2 months after patch testing, it was demonstrated 
that patients confirmed as having contact allergy showed a subsequent improvement in 
eczema severity and an improvement in quality of life (21). A clinical follow-up study on 105 
formaldehyde allergic patients showed by examination that patients’ dermatitis had 
generally improved from their first visit to the department (20 ?). It was also seen that 
patients who paid attention to their allergy had statistically significantly fewer eruptions 
than those who did not (20). In another study from US showed that allergic contact 
dermatitis had an appreciable effect on quality of life, especially when it affected the hands, 
the face, or was occupationally related (reference ?). It was shown that outcomes in patients 
with allergic contact dermatitis were improved by early diagnosis (23). In UK an audit on the 
value of patch testing was done from the patients’ perspective. It showed that patch testing 
  
was beneficial, especially for those with allergic contact dermatitis. Patients' knowledge of 
the results was good but education could be improved (24). In our study only patients with 
positive patch tests to MI were included however in a study from US following up 431 
patients with suspected allergic contact dermatitis, there was significantly better 
improvement in each of quality of life among patch tested subjects compared with non-
patch-tested subjects (25). 
During this epidemic many people in the European population has become sensitized. The 
big hurdle is that many of these probably do not have access to dermatology care and patch 
testing. It has been estimated that 15-38% of patients with allergic contact dermatitis in 
Germany (26) and 20%-30% in Denmark (27), are seen by a dermatologist and relevantly 
patch tested. These countries have free access to health care services, so the situation in 
some other countries may be much worse. This mean that patch test data show the tip of 
the iceberg and a large pool of individuals are sensitized but not diagnosed with contact 
allergy e. g. to MI and cannot benefit from advice and labelling. They will continue to have 
symptoms unless other preventive actions are launched such as restrictions or bans of the 
substance.  
In conclusion the severity of MI allergic contact dermatitis and impact on daily living 
documents the need for prevention. 
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Questionnaire on MI-allergy and exposures: Patient form (A)  
         To be filled in for each patient with contact dermatitis at their first consultation 
 
 Patient initials………………   Date……… 
 
Sex 
 
  male 
 
Age in years…………………….. 
   female  Occupation………………. 
 
Job title (ISCO-08 #): ..........................................................................................(...............) 
Start of job: ....../ ......./ .................      End of job: ....../ ......./ ...................   or ongoing [   ] 
 
Specific tasks: ....................................................................................................................... 
 
Contact materials: [.......]          [.......]          [.......] ]          [.......]  (use ESSCA catalogue) 
 
Protective measures: ............................................................................................................ 
 
Severity1 
Physicians Global Assessment (VAS).  
How severe is the current dermatitis?  
0                                                                                          100 
|----------------------------------------------------------------------| 
No dermatitis                                                                                               Very severe 
 
Quality of Life1, (ask the patient set a mark on the line) 
Patients own global assessment.  
How much does your skin disease influence you daily life/quality of life negatively?  
Think about the past week. 
0                                                                                          100 
|----------------------------------------------------------------------| 
No influence                                                                                         It could not be worse 
                                                                             
Localisation of Dermatitis                                                                              yes   no 
Present dermatitis                      Atopic dermatitis, presently          
 Hands                      Atopic dermatitis, previously        
 Arms                      if yes, age of debut of AD ________________ 
 Trunk                                                            yes  no 
 Neck                      Previously patch tested:      year______   
 Eyes                                                                              yes  no 
 Scalp                      Known positive to MI or MI/MCI:      
 Face(rest) 
Legs 
 
 
 Feet                
                   Genital/ano area  
                                                          
1 This information should be filled in at the first consultation, not after dermatitis has subsided when the patch 
test is performed 
  
No present dermatitis              
Onset of present dermatitis: month_______  year________ 
 
 
 
Patient form (B) p.1:  
only for patients with a positive reaction (at least +) to MI 
 
Patient initials………………   Date………………   
 
 
Patch test results: (only record if positive at -at least one reading)  
          Current test reaction  
Test preparation D2 D3/
4 
D5/
7 
Comments 
Methylisothiazolinone 0.2%     
MCI/MI 0.02%     
Fragrance mix I     
Fragrance mix II/HICC     
Balsam of Peru     
Formaldehyde      
Quaternium 15     
Parabens     
Nickel     
Chromium     
Cobalt     
Others from baseline series 
: 
    
     
     
     
     
                  (+++, ++, + allergic reaction; IR irritant reaction; (+) or ? doubtful reaction) 
 
 
 
Comments:_____________________________________________________________________ 
 
______________________________________________________________________________ 
 
 
 
  
 
Patient form (B) p.2                                             Patient initials………………    
Table X.: Number of products brought in by the patients in the different categories 
Products used by the patient containing MI or MCI/MI (determined from ingredient 
labelling, MSDS (incl. internet), contact to manufacturer or chemical analysis) 
Product type Number of products with: 
    MI                  MCI/MI 
Used in 
Private life 
Used  
occupationally 
Creams/Lotions     
-body     
-face     
-eyes     
-hands     
-feet     
Sunscreens     
Self-tanning     
Deodorant     
-spray     
-roll-on/stick     
Make-up     
-face masks     
-eye make-up     
-tinted bases     
-make-up remover     
Wet wipes     
Hairstyling     
-gels/mousse     
 -sprays     
Nail care     
Mouths washes     
Rinse-of cosmetics     
-liquid soap     
-bath/shower gel     
-shampoo     
-conditioner     
Shaving products     
Cleaning agents     
Household cleaning spray     
Dishwashing liquid     
Paints     
Glues     
Cutting oils     
Others (write which):     
     
     
     
     
 
  
Patient form (B) p.3                                            Patient initials………………    
 
Current relevance: If you judge any of the above products to have caused or 
contributed to the (current) dermatitis. Please give more details her: 
Product type name producer Comments eg. Batch 
no. 
    
    
    
    
    
    
    
 
 
Airborne exposures? 
 
Reacted in newly painted rooms?     Yes       No  
If yes: 
With dermatitis    
With rhinitis         
With asthma(like) symptoms  
With conjunctivitis                 
 
Reacted to other airborne exposure? Yes       No  
If yes: 
Type of exposure:_______________________________________ 
 
Reaction type: 
With dermatitis      
With rhinitis          
With asthma(like) symptoms  
With conjunctivitis                 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
  
 
Questionnaire on MI-allergy and exposures: Clinic form (C) 
 
 
  
Study started: _____/_____/_____    Study ended_____/_____/_____ 
 
  
Number of patients tested with MI in total:  
…………………………………………………………... 
  
Number of females tested:  …………………………………………………………... 
  
Number of males tested:  …………………………………………………………….. 
 
 
 
 
  
Patient follow-up form (D) p.1: only for patients with MI allergy                                  
 
Patient initials………………                                 date:……………………….    
 
 
Follow-up time:……………………. months 
(time since patch testing eg. 3 months) 
 
 
Severity 
Physicians Global Assessment (VAS) :  
0                                                                                          100 
|----------------------------------------------------------------------| 
No dermatitis                                                                                                Very severe 
 
 
Quality of Life, (ask the patient set a mark on the line) 
Patients own global assessment.  
How much does your skin disease influence you daily life/quality of life negatively?  
Think about the past week. 
 
0                                                                                          100 
|----------------------------------------------------------------------| 
No influence                                                                                            It could not be worse 
 
 
Consequences from MI contact allergy 
[   ]  Sick-leave      if yes how many weeks the last year due to (MI)dermatitis………………. 
[   ]  In-patient treatment 
[   ]  Job change 
[   ]  Job loss and unemployed 
 
 
Other relevant information: 
 
_______________________________________________________ 
 
  
 
